|
See related Stelara inj information |
|
|
|
Manufacturer |
Janssen |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Ustekinumab |
|
Indications |
Treatment of patients w/ chronic moderate to severe plaque psoriasis who are candidates for photo- or systemic therapy. |
|
Dosage |
Adult 45 mg at wk 0 & 4 then every 12 wk thereafter. Patient w/ body wt >100 kg 90 mg. |
|
Contraindications |
Severe infections eg sepsis, TB & opportunistic infections. |
|
Special Precautions |
Carcinogenic & mutagenic, history of malignancy, hepatic & renal insufficiency, anaphylactic or other serious allergic reaction, immunization & immunosuppression, chronic infection or history of recurrent infection. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Serious infections, malignancies, nasopharyngitis, upper resp tract infections, headache, fatigue, diarrhea, back pain, dizziness, pharyngolaryngeal pain, pruritus, inj site erythema, myalgia, depression.
View ADR Monitoring Form |
|
Drug Interactions |
Live vaccines, immunosuppressants.
View more drug interactions with Stelara |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
ATC Classification |
L04AC05 - ustekinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Stelara injection |
|
Stelara 45 mg/0.5 mL x 1's |
|
|
|
Manufacturer: |
Janssen |
|
Distributor: |
Hong Kong: DKSH
Macau: Four Star
|
|
|
|
